Core Insights - HUTCHMED (China) Limited announced positive data from the Phase 3 registration part of the ESLIM-02 clinical trial for sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) [1][4] Clinical Trial Results - The ESLIM-02 trial met its primary endpoint of durable hemoglobin response rate between weeks 5 to 24 of treatment [2] - The overall response rate was 43.8% in the first 8 weeks and 66.7% during the 24 weeks of treatment, compared to 0% in the placebo group [4] - The study included patients who had relapsed or were refractory to at least one prior line of standard treatment [3] Disease Prevalence and Impact - The incidence of autoimmune hemolytic anemia (AIHA) is estimated at 0.8-3.0 per 100,000 adults annually, with a prevalence of 17 per 100,000 adults and a death rate of 8-11% [2] - wAIHA accounts for approximately 75-80% of all adult AIHA cases [2] Regulatory Plans - HUTCHMED plans to submit a New Drug Application for sovleplenib for wAIHA to the China National Medical Products Administration (NMPA) in the first half of 2026 [4] Competitive Landscape - Novartis AG reported results from the VAYHIT2 Phase 3 trial showing that ianalumab plus eltrombopag had a median time to treatment failure 2.8 times longer than placebo plus eltrombopag [6] - CRISPR Therapeutics AG initiated a Phase 1 trial of its allogeneic CAR T therapy in ITP and wAIHA [6] Other Developments - HUTCHMED initiated the Phase 3 part of a trial for a combination treatment for metastatic pancreatic ductal adenocarcinoma [7] - HUTCHMED shares increased by 5.09% to $14.45 during premarket trading [7]

Summary of China Healthcare & Pharmaceuticals 3Q25 Drug Sales Tracker Industry Overview - The report focuses on the **China healthcare and pharmaceuticals industry**, specifically analyzing drug sales data for the third quarter of 2025 (3Q25) [1][2]. Key Findings - **Overall Market Performance**: The overall drug market sales in China declined by **6.2% year-on-year (y-y)** but increased by **6% quarter-on-quarter (q-q)**, totaling **CNY 226 billion** in 3Q25 [2][1]. - **Performance of Domestic Pharma Companies**: - **Hengrui**: Sales decreased by **0.1% y-y** to **CNY 5.8 billion**. - **Sinobio**: Sales fell by **0.9% y-y** to **CNY 4.1 billion**. - **Hansoh**: Sales declined by **0.8% y-y** to **CNY 2.0 billion**. - **Qilu Pharma**: Experienced a **9% y-y decline** to **CNY 4.7 billion**. - **CSPC**: Sales dropped by **17% y-y** to **CNY 3.6 billion** [4][4]. - **Biotech Companies' Growth**: - **BeOne**: Sales increased by **20.4% y-y** to **CNY 1.5 billion**. - **Innovent**: Sales rose by **24.6% y-y** to **CNY 1.5 billion**. - **Akeso**: Notable growth of **130.1% y-y** to **CNY 156 million**. - **Remegen**: Sales grew by **54.2% y-y** to **CNY 255 million** [5][5]. - **Multinational Corporations (MNCs) Performance**: - **AstraZeneca**: Sales decreased by **4.9% y-y** to **CNY 6.1 billion**. - **Novartis**: Sales fell by **7.3% y-y**. - **Roche**: Sales declined by **13.6% y-y**. - **Pfizer**: Sales dropped by **13.9% y-y** [6][6]. - **Notable Growth in Specific Products**: - **Novo Nordisk**: Sales increased by **22.3% y-y** to **CNY 3.7 billion**, driven by **Semaglutide** sales growth of **35% y-y** to **CNY 1.3 billion**. - **Eli Lilly**: Sales of **Tirzepatide** reached **CNY 2 million** in 3Q25 [7][7]. Additional Insights - **Hengrui's Specific Products**: - **Camrelizumab**: Sales rose by **34% y-y** to **CNY 445 million**. - **Pyrotinib**: Sales remained flat at **CNY 280 million**. - **Mecapegfilgrastim**: Sales increased by **4% y-y** to **CNY 435 million** [9][9]. - **Sinobio's Product Performance**: - **Anlotinib**: Sales grew by **6% y-y** to **CNY 646 million**. - **Magnesium Isoglycyrrhizinate**: Sales increased by **7% y-y** to **CNY 682 million** [9][9]. - **CSPC's Oncology Drugs**: - **Duomeisu**: Sales surged by **91% y-y** to **CNY 40 million**. - **Jinyouli**: Sales declined by **19% y-y** to **CNY 609 million** [10][10]. - **Hansoh's Oncology Drugs**: - **Almonertinib**: Sales rose by **14% y-y** to **CNY 560 million**. - **Flumatinib**: Sales increased by **25% y-y** to **CNY 185 million** [10][10]. Conclusion - The China healthcare and pharmaceuticals market is experiencing mixed results, with domestic companies facing declines while biotech firms show significant growth. MNCs are also struggling, indicating a challenging environment for the industry overall. The data suggests potential investment opportunities in biotech companies that are outperforming their peers.